Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 26 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Dimopoulos, Meletios A  [Clear All Filters]
2019
Liapis, K., Panagopoulou P., Charitaki E., Rowczenio D., Gilbertson J., Papathoma A., et al. (2019).  Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variant.. Amyloid. 26(1), 52-53.
2018
Ziogas, D. C., Terpos E., Gavriatopoulou M., Migkou M., Fotiou D., Roussou M., et al. (2018).  Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases.. Leuk Lymphoma. 59(4), 983-987.
Bagratuni, T., Ntanasis-Stathopoulos I., Gavriatopoulou M., Mavrianou-Koutsoukou N., Liacos C., Patseas D., et al. (2018).  Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies.. Leukemia.
Kastritis, E., Kostopoulos I. V., Terpos E., Paiva B., Fotiou D., Gavriatopoulou M., et al. (2018).  Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.. Blood Cancer J. 8(5), 46.
Kastritis, E., Papassotiriou I., Merlini G., Milani P., Terpos E., Basset M., et al. (2018).  Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis.. Blood. 131(14), 1568-1575.
Fotiou, D., Dimopoulos M. A., & Kastritis E. (2018).  How We Manage Patients with Plasmacytomas.. Curr Hematol Malig Rep. 13(3), 227-235.
Katodritou, E., Terpos E., Delimpasi S., Kotsopoulou M., Michalis E., Vadikolia C., et al. (2018).  Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.. Blood Cancer J. 8(3), 31.
2017
Dimopoulos, M. A., Roussou M., Gavriatopoulou M., Psimenou E., Ziogas D., Eleutherakis-Papaiakovou E., et al. (2017).  Cardiac and renal complications of carfilzomib in patients with multiple myeloma.. Blood Adv. 1(7), 449-454.
Kastritis, E., Terpos E., Roussou M., Gavriatopoulou M., Migkou M., Eleutherakis-Papaiakovou E., et al. (2017).  Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.. Haematologica. 102(3), 593-599.
Ziogas, D. C., Kastritis E., Terpos E., Roussou M., Migkou M., Gavriatopoulou M., et al. (2017).  Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens.. Leuk Lymphoma. 58(8), 1832-1839.
Kastritis, E., Gavriatopoulou M., Roussou M., Migkou M., Fotiou D., Ziogas D. C., et al. (2017).  Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy.. Am J Hematol. 92(7), 632-639.
2016
Dimopoulos, M. A., Roussou M., Gavriatopoulou M., Psimenou E., Eleutherakis-Papaiakovou E., Migkou M., et al. (2016).  Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.. Am J Hematol. 91(5), 499-502.
Fotiou, D., Dimopoulos M. A., & Kastritis E. (2016).  Managing renal complications in multiple myeloma.. Expert Rev Hematol. 9(9), 839-50.
2015
Kastritis, E., Gavriatopoulou M., Kyrtsonis M-C., Roussou M., Hadjiharissi E., Symeonidis A., et al. (2015).  Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.. Blood. 126(11), 1392-4.
Koutsoukos, K., Tzannis K., Christodoulou C., Karavasilis V., Bakoyiannis C., Makatsoris T., et al. (2015).  Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG).. World J Urol.
2014
Pentheroudakis, G., Kotoula V., Kouvatseas G., Charalambous E., Dionysopoulos D., Zagouri F., et al. (2014).  Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.. Clin Breast Cancer. 14(5), 330-8.
Karavasilis, V., Kosmidis P., Syrigos K. N., Mavropoulou P., Dimopoulos M. A., Kotoula V., et al. (2014).  Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group.. Anticancer Res. 34(10), 5649-55.
Purrington, K. S., Slager S., Eccles D., Yannoukakos D., Fasching P. A., Miron P., et al. (2014).  Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.. Carcinogenesis. 35(5), 1012-9.
2013
Fountzilas, G., Dafni U., Bobos M., Kotoula V., Batistatou A., Xanthakis I., et al. (2013).  Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy.. BMC Cancer. 13, 163.
Stavropoulou, A. V., Fostira F., Pertesi M., Tsitlaidou M., Voutsinas G. E., Triantafyllidou O., et al. (2013).  Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases.. PLoS One. 8(3), e58182.
Pentheroudakis, G., Kotoula V., Eleftheraki A. G., Tsolaki E., Wirtz R. M., Kalogeras K. T., et al. (2013).  Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).. PLoS One. 8(7), e70634.
2012
Fountzilas, G., Dafni U., Bobos M., Batistatou A., Kotoula V., Trihia H., et al. (2012).  Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.. PLoS One. 7(6), e37946.
Gogas, H., Dafni U., Karina M., Papadimitriou C., Batistatou A., Bobos M., et al. (2012).  Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.. Breast Cancer Res Treat. 132(2), 609-19.
2011
Papadimitriou, C. A., Papakostas P., Karina M., Malettou L., Dimopoulos M. A., Pentheroudakis G., et al. (2011).  A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.. BMC Med. 9, 10.
2010
Bamias, A., Karadimou A., Lampaki S., Lainakis G., Malettou L., Timotheadou E., et al. (2010).  Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model.. BMC Cancer. 10, 45.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές